

REMARKS

By this amendment claims 6, 8, 11 and 19 are canceled; and claims 9, 12, 17, 20, 22 and 24 are amended. Claims 9, 10, 12, 17, 18, 20 and 22-25 are pending. No issue of new matter arises. Entry of the amendment and reconsideration and withdrawal of all pending rejections in each of the multiple parts thereof are respectfully requested.

Rejection under 35 U.S.C. §103(a)

At page 2, the Advisory Action rejected maintained the rejection under 35 U.S.C. §103(a) over Citron in view of St. George-Hyslop, Ishii, Borchelt and Xia. Claims 12 and 20 are hereby amended and now recite 5 specific mutations not taught or suggested by the applied references. Since these claims include elements not taught or suggested by the applied references they cannot properly be considered obvious over these references. Dependent claims are patentable over the prior art for at least the same reasons that the claims from which they depend are patentable over the prior art. Reconsideration and withdrawal of this rejection of all pending claims are respectfully requested.

Conclusion

In view of the above amendments and remarks, Applicants respectfully submit that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance. Should the Examiner wish to suggest additional changes that might put the application in even better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.

Fees

The Commissioner is hereby authorized to charge any fee required for added claims and any additional fees that may be needed to Deposit Account No. 18-1982.

Respectfully submitted,

Dated: January 10, 2011

/George S Jones/
George S. Jones, Reg. No. 38,508
Attorney for Applicants

Sanofi-aventis U.S. Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3776
Telefax: 908-231-2626
sanofi-aventis Docket No. ST99042 US PCT